674 related articles for article (PubMed ID: 29961183)
21. Combining oncolytic virotherapy and tumour vaccination.
Bridle BW; Hanson S; Lichty BD
Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
[TBL] [Abstract][Full Text] [Related]
22. Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.
Li QX; Liu G; Zhang X
Curr Pharm Biotechnol; 2012 Jul; 13(9):1773-85. PubMed ID: 21740353
[TBL] [Abstract][Full Text] [Related]
23. Tailoring early-phase clinical trial design to address multiple research objectives.
Wages NA; Slingluff CL; Bullock TN; Petroni GR
Cancer Immunol Immunother; 2020 Jan; 69(1):95-102. PubMed ID: 31807879
[TBL] [Abstract][Full Text] [Related]
24. Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.
Rafei-Shamsabadi D; Lehr S; von Bubnoff D; Meiss F
Cancer Immunol Immunother; 2019 Sep; 68(9):1417-1428. PubMed ID: 31422446
[TBL] [Abstract][Full Text] [Related]
25. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Engeland CE; Grossardt C; Veinalde R; Bossow S; Lutz D; Kaufmann JK; Shevchenko I; Umansky V; Nettelbeck DM; Weichert W; Jäger D; von Kalle C; Ungerechts G
Mol Ther; 2014 Nov; 22(11):1949-59. PubMed ID: 25156126
[TBL] [Abstract][Full Text] [Related]
26. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress.
Myint ZW; Goel G
J Hematol Oncol; 2017 Apr; 10(1):86. PubMed ID: 28434400
[TBL] [Abstract][Full Text] [Related]
27. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
[TBL] [Abstract][Full Text] [Related]
28. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA
Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585
[TBL] [Abstract][Full Text] [Related]
29. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
Barker CA; Postow MA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):986-97. PubMed ID: 24661650
[TBL] [Abstract][Full Text] [Related]
30. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.
Mocellin S; Rossi CR; Nitti D; Lise M; Marincola FM
Biochim Biophys Acta; 2003 Dec; 1653(2):61-71. PubMed ID: 14643925
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic virus immunotherapy: future prospects for oncology.
Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
[TBL] [Abstract][Full Text] [Related]
32. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
[TBL] [Abstract][Full Text] [Related]
33. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
34. Immune based therapy for melanoma.
Ancuceanu R; Neagu M
Indian J Med Res; 2016 Feb; 143(2):135-44. PubMed ID: 27121512
[TBL] [Abstract][Full Text] [Related]
35. Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.
Shi T; Ma Y; Yu L; Jiang J; Shen S; Hou Y; Wang T
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29735917
[TBL] [Abstract][Full Text] [Related]
36. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
[TBL] [Abstract][Full Text] [Related]
37. What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?
Donnelly OG; Melcher AA; Vile RG; Pulido J
Immunotherapy; 2012 Aug; 4(8):749-51. PubMed ID: 22947000
[No Abstract] [Full Text] [Related]
38. Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers.
Song XT
Discov Med; 2013 Dec; 16(90):261-6. PubMed ID: 24333405
[TBL] [Abstract][Full Text] [Related]
39. Talimogene laherparepvec in the treatment of melanoma.
Appleton ES; Turnbull S; Ralph C; West E; Scott K; Harrington K; Pandha H; Melcher A
Expert Opin Biol Ther; 2015; 15(10):1517-30. PubMed ID: 26629575
[TBL] [Abstract][Full Text] [Related]
40. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.
Ollila DW; Kelley MC; Gammon G; Morton DL
Semin Surg Oncol; 1998 Jun; 14(4):328-36. PubMed ID: 9588726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
